1. Home
  2. Azioni
  3. Stati Uniti
  4. Nasdaq
  5. Ocugen, Inc.
  6. Notizie
  7. Altre lingue
    OCGN   US67577C1053

OCUGEN, INC.

(OCGN)
  Rapporto
Tempo reale stimato Cboe BZX  -  18/05 16:08:28
2.235 USD   +0.68%
09/05OCUGEN, INC.: per Chardan Research il titolo è Neutral
MM
09/05OCUGEN, INC.: Chardan Research ribadisce il giudizio Neutral
MM
06/05La perdita netta del Q1 di Ocugen si allarga
MT
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietàFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su OCUGEN, INC.
13/05INSIDER SELL: Ocugen
06/05OCUGEN, INC. Management's Discussion and Analysis of Financial Condition and Results o..
06/05TRANSCRIPT: Ocugen, Inc., Q1 2022 Earnings Call, May 06, 2022
06/05Ocugen's Q1 Net Loss Widens
06/05OCUGEN, INC.: Results of Operations and Financial Condition, Other Events, Financial Stat..
06/05Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
06/05OCUGEN: Q1 Earnings Snapshot
06/05Ocugen Provides Business Update and First Quarter 2022 Financial Results
02/05OCUGEN TO HOST CONFERENCE CALL ON FR: 30 a.m. ET to Provide Business Update and Discuss F..
29/04Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision a..
28/04Ocugen, Inc. Announces Manish Potti Will Not Stand for Re-Election as Class II Director
25/04Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
25/04Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
25/04Certain Common Stock of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 25-AP..
25/04Certain Preferred Stock of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 25..
25/04Certain Warrants of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-20..
25/04Certain Restricted Stock Units of Ocugen, Inc. are subject to a Lock-Up Agreement Endin..
25/04Certain Stock Options of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 25-A..
20/04OCUGEN, INC.: Other Events, Financial Statements and Exhibits (form 8-K)
19/04Ocugen, Inc. to Present at NobleCon18
18/04OCUGEN, INC.: Entry into a Material Definitive Agreement (form 8-K)
18/04Ocugen, Inc. and Bharat Biotech International Limited Enters into Second Amendment to C..
18/04Ocugen Obtains Commercialization Rights of Covaxin in Mexico
18/04Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of ..
12/04Ocugen's Study of COVID-19 Vaccine Put on Clinical Hold After Issues at Bharat Biotech ..
12/04OCUGEN: Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152) - Form 8-K
12/04OCUGEN, INC.: Other Events, Financial Statements and Exhibits (form 8-K)
12/04Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)
12/04Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™
12/04OCUGEN: FDA Has Placed Co.'s Covid Vaccine Trial on Clinical Hold
04/04OCUGEN, INC.: Other Events, Financial Statements and Exhibits (form 8-K)
01/04Ocugen Doses First Patient in Phase 1/2 Trial of Gene Therapy to Treat Retinal Degenera..
01/04Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy..
01/04Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy..
23/03OCUGEN, INC.: Change in Directors or Principal Officers (form 8-K)
23/03Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors
23/03Ocugen, Inc. Announces Board Changes
22/03Ocugen Promotes Jessica Crespo to Chief Accounting Officer
21/03Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice ..
21/03Ocugen, Inc. Appoints Jessica Crespo as Chief Accounting Officer and Senior Vice Presid..
18/03Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/03OCUGEN, INC.: Other Events, Financial Statements and Exhibits (form 8-K)
09/03Ocugen, Inc. to Present at the 34th Annual ROTH Conference
08/03Inozyme Pharma Appoints Former Ocugen Finance Chief Sanjay Subramanian in Same Role
07/03Ocugen Provides an Update on its COVAXIN Pediatric (2-18) Emergency Use Authorization (..
04/03OCUGEN: Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authoriza..
04/03OCUGEN, INC.: Change in Directors or Principal Officers, Other Events, Financial Statemen..
04/03Ocugen, Inc. Announces Resignation of Sanjay S. Subramanian as Chief Financial Officer
04/03Ocugen, Inc. Announces Executive Changes
04/03SECTOR UPDATE: Health Care Investors Squaring Positions Ahead of Weekend Break
04/03SECTOR UPDATE: Health Care Stocks Recovering This Afternoon
04/03Ocugen Shares Hit 52-Week Low After FDA Declines EUA for Covaxin
04/03SECTOR UPDATE: Health Care Stocks Retreat Pre-Bell Friday
04/03Wall Street Set for Downbeat Session as Ukraine Crisis Deepens, Strong US Jobs Report C..
04/03SECTOR UPDATE: Health Care
04/03Top Premarket Decliners
04/03Ocugen Says FDA Rejects Emergency Use Authorization For Covaxin COVID Vaccine Candidate..
04/03OCUGEN: FDA Declines EUA for Covid-19 Vaccine in Ages 2 to 18
04/03Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authoriz..
04/03Ocugen, Inc. Provides Update on its COVAXIN™ Pediatric (2-18) Emergency Use Author..
28/02Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Result..
28/02OCUGEN, INC. Management's Discussion and Analysis of Financial Condition and Results o..
28/02Ocugen, Inc. Auditor Raises 'Going Concern' Doubt
25/02SECTOR UPDATE: Health Care Stocks Mixed Pre-Bell Friday
25/02TRANSCRIPT: Ocugen, Inc., Q4 2021 Earnings Call, Feb 25, 2022
25/02Ocugen Posts Wider Q4 Net Loss
25/02OCUGEN: Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results..
25/02OCUGEN: Q4 Earnings Snapshot
25/02Ocugen, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended Decemb..
25/02OCUGEN, INC.: Entry into a Material Definitive Agreement, Financial Statements and Exhibi..
25/02Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Result..
23/02SECTOR UPDATE: Health Care Stocks Unable to Retain Midday Rise
23/02Ocugen Prices $53.5 Million Common Stock Offering; Shares Sink
23/02SECTOR UPDATE: Health Care Stocks Higher in Wednesday Trading
23/02Ocugen Prices $53.5 Million Common Stock Offering
1  2  3  4  5  6  7  8  9  10Pross.
Prossimo evento su OCUGEN, INC.